このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency Genes (IKF-IMMUPARP)

Phase II Study of Immunotherapy Plus PARP Inhibition Maintenance for Platinum-Sensitive Biliary Tract Cancer With Mutations in Core- and Non-Core Homologous Recombination Deficiency Genes

The IMMUPARP study is an open-label, multicenter phase II trial investigating maintenance therapy with olaparib plus durvalumab in patients with platinum-sensitive advanced biliary tract cancer harboring homologous recombination deficiency (HRD)-associated gene alterations after response or stable disease on first-line chemoimmunotherapy.

調査の概要

状態

まだ募集していません

詳細な説明

The goal of this phase II clinical trial is to evaluate the efficacy and safety of maintenance therapy with the PARP inhibitor olaparib in combination with the PD-L1 inhibitor durvalumab in adult patients with platinum-sensitive unresectable locally advanced or metastatic biliary tract cancer (BTC) harboring homologous recombination deficiency (HRD)-associated gene alterations. Eligible patients must have achieved stable disease or an objective response following first-line treatment with gemcitabine, cisplatin and immunotherapy.

The main questions it aims to answer are:

Does maintenance treatment with olaparib plus durvalumab result in a clinically meaningful progression-free survival (PFS) rate at 6 months? What are the progression-free survival, overall survival, response outcomes, and duration of disease control associated with this treatment approach? What is the safety and tolerability profile of olaparib plus durvalumab maintenance therapy? How does maintenance treatment affect patient-reported quality of life?

This is a prospective, multicenter, open-label, non-randomized phase II trial consisting of two cohorts. Cohort 1 includes patients with alterations in core HRD genes (e.g., BRCA1, BRCA2, PALB2 or RAD51C/D), while Cohort 2 includes patients with alterations in non-core HRD genes.

There is no comparison group. All participants will receive study treatment consisting of olaparib administered orally twice daily and durvalumab administered intravenously every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or completion of the protocol-defined treatment period.

Participants will:

Receive olaparib and durvalumab maintenance therapy. Undergo regular tumor assessments by CT or MRI every 8 weeks. Complete quality-of-life questionnaires during the study. Undergo routine safety assessments, including physical examinations and laboratory testing.

Optionally provide blood and tumor samples for translational biomarker analyses, including evaluation of HRD status and circulating tumor DNA (ctDNA).

The study aims to generate prospective evidence on the clinical activity of combined PARP inhibition and immune checkpoint blockade as a maintenance strategy in molecularly selected patients with advanced BTC.

Up to 40 patients will be enrolled across both cohorts.

研究の種類

介入

入学 (推定)

40

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Patient* has given written informed consent.

  2. Patient is, in the investigator's judgement, willing and able to comply with the trial protocol.

  3. Patient is ≥ 18 years of age at time of signing the written informed consent.

  4. Patient has been diagnosed with histologically confirmed unresectable locally advanced or metastatic biliary tract cancer.

  5. Patient has platinum-sensitive BTC, i.e., shows stable disease or partial response after at least 4 months of SOC treatment with GemCis plus durvalumab.

  6. Cohort 1 only: Patient has BTC with mutations in Core HRD genes, including germline/somatic (gs) mutation of BRCA1, BRCA2, PALB2 or RAD51C/D (assessed by local testing) or Cohort 2 only: BTC with mutations in Non-Core HRD genes, including ATM, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51B, RTEL1, MUTYH (assessed by local testing) .

  7. Patient has ECOG performance status ≤ 1.

  8. Patient has adequate hepatic, renal and hematologic functions:

    1. Absolute number of neutrophils (ANC) ≥ 1.5 x 109/L
    2. Platelets ≥ 100x103/µL
    3. Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L (Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within the last 2 weeks)
    4. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl; measured and calculated per institutional standard) ≥ 60 mL/min (i.e., if serum creatinine level is > 1.5 x upper limit of normal [ULN]). GFR can also be used instead of creatinine or CrCl.
    5. AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN (or ≤ 5.0 x ULN if liver metastases are present)
    6. Total Bilirubin ≤ 1.5 x ULN (or direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5× ULN)
    7. International normalized ratio (INR) OR prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless patient is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants.
  9. Male patients must agree to use a contraception as detailed in Appendix 5 of this protocol during the treatment period and for at least 3 months after the last dose of trial treatment (and refrain from donating sperm during this period.

Female patients are eligible to participate if they are not pregnant (see Appendix 5), not breastfeeding, and at least one of the following conditions applies:

  • Not a woman of childbearing potential (WOCBP) as defined in Appendix 5 OR
  • A WOCBP who agrees to follow the contraceptive guidance as given in Appendix 5 during the treatment period and for at least 6 months after the last dose of trial intervention 10. Patient has measurable disease based on RECIST v1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions

Exclusion Criteria:

  1. Patient has any known contraindication including hypersensitivity to any component of the PARP inhibitor or durvalumabformulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.

  2. Patient has received prior treatment with PARP inhibitors.

  3. Patient is currently participating in or has participated in a trial of an investigational medicinal product or has used an investigational medicinal product within 4 weeks prior to the first dose of trial intervention.

    NOTE: Patients who have entered the follow-up phase of an investigational trial may participate as long as it has been 4 weeks after the last dose of the previous investigational medicinal product .

  4. Patient has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial drug.

  5. Patient has known additional malignancy that is progressing or has required active treatment within the past 3 years.

    Note: Participants with low risk localized prostate cancer, basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded.

  6. Patient has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during trial screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of trial intervention.

  7. Patient has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.

  8. Patient has a history of pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.

  9. Patient has an active infection requiring systemic therapy.

  10. Patient has a known history of Human Immunodeficiency Virus (HIV) infection.

  11. Patients with known Hepatitis B and C infection expect the following:

    1. Hepatitis B positive subjects

      • Patients who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load (< 100 IU/mL) prior to enrollment
      • Patients should remain on anti-viral therapy throughout trial intervention and follow local guidelines for HBV anti-viral therapy post completion of trial intervention.
    2. Patients with a history of HCV infection are eligible if HCV viral load is undetectable at screening.

      • Patients must have completed curative anti-viral therapy at least 4 weeks prior to enrollment.

    NOTE: Hepatitis B and C screening tests are not required unless there is a known history of HBV or HCV infection and/or as mandated by local health authority

  12. Patient has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, such that it is not in the best interest of the patient to participate, in the opinion of the treating investigator.

  13. Patient has had an allogenic tissue / solid organ transplant.

  14. Patients who are pregnant or breastfeeding or expect to conceive (female patients) within 6 months or father children (male patients) within the projected duration of the trial, starting with the screening visit through 3 months after the last dose of trial treatment.

  15. Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan, previous allogenic bone marrow/blood transplantation or any psychiatric disorder or substance abuse that prohibits obtaining informed consent

  16. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.

  17. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].

  18. Patients who are dependent on the sponsor, the investigator or the trial site.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort 1: Core HRD

Experimental maintenance:

Olaparib: orally, 2 x 300 mg daily, continuously PLUS Durvalumab: 1,500 mg, i.v., on day 1 of every 4-week cycle (Q4W) Patients will receive treatment until progression, unacceptable toxicity, withdrawal of consent, or end of protocol-defined treatment (maximum of 12 months).

Experimental maintenance: Olaparib: orally, 2 x 300 mg daily, continuously PLUS Durvalumab: 1,500 mg, i.v., on day 1 of every 4-week cycle (Q4W) (maximum of 12 months).

実験的:Cohort 2: Non-Core HRD

Experimental maintenance:

Olaparib: orally, 2 x 300 mg daily, continuously PLUS Durvalumab: 1,500 mg, i.v., on day 1 of every 4-week cycle (Q4W) Patients will receive treatment until progression, unacceptable toxicity, withdrawal of consent, or end of protocol-defined treatment (maximum of 12 months).

Experimental maintenance: Olaparib: orally, 2 x 300 mg daily, continuously PLUS Durvalumab: 1,500 mg, i.v., on day 1 of every 4-week cycle (Q4W) (maximum of 12 months).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
PFS rate at 6 months
時間枠:6 months after start of maintenance therapy

PFS rate at 6 months (PFS@6), defined as proportion of patients alive and progression-free at 6 months after start of maintenance therapy

6 months after start of maintenance therapy

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall response rate
時間枠:up to 12 months

Overall response rate (ORR), defined as proportion of patients achieving complete or partial response (CR/PR) acc. to RECIST v1.1.

up to 12 months
Overall survival
時間枠:up to 36 months

Overall survival (OS), defined as time from start of induction therapy until date of death due to any cause.

up to 36 months
Overall survival (OSmaint)
時間枠:up to 36 months

Overall survival (OSmaint), defined as time from start of maintenance therapy until date of death due to any cause.

up to 36 months
Progression-free survival
時間枠:up to 36 months

Progression-free survival (PFS), defined as time from start of induction therapy until date of progression acc. to RECIST v1.1 or death due to any cause.

up to 36 months
Progression-free survival (PFSmaint)
時間枠:up to 36 months

Progression-free survival (PFSmaint), defined as time from start of maintenance therapy until date of progression acc. to RECIST v1.1 or death due to any cause.

up to 36 months
Quality of life (QoL) data (EORTC QLQ-C30) Functional Scale Scores
時間枠:up to 13 months

Quality of life will be assessed using the EORTC QLQ-C30 questionnaire. Functional scale scores (Physical Functioning, Role Functioning, Emotional Functioning, Cognitive Functioning, and Social Functioning) are transformed to a 0-100 scale. Scores range from 0 to 100, with higher scores indicating better functioning

up to 13 months
Safety
時間枠:up to 15 months (max. 12 months treatment plus 90 days for immune-mediated AEs)

Assessment of safety of the treatment as determined by the incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 6.0

up to 15 months (max. 12 months treatment plus 90 days for immune-mediated AEs)
Quality of life (QoL) data (EORTC QLQ-C30) Symptom Scale Scores
時間枠:up to 13 months

Quality of life will be assessed using the EORTC QLQ-C30 questionnaire. Symptom scale and single-item scores are transformed to a 0-100 scale. Scores range from 0 to 100, with higher scores indicating greater symptom burden and worse quality of life.

up to 13 months
Quality of life (QoL) data (EQ-5D-5L) Health Utility Index Score
時間枠:up to 13 months

Health status will be assessed using the EQ-5D-5L descriptive system. The health utility index score is calculated from the five EQ-5D-5L dimensions using the applicable country-specific value set. The score typically ranges from values below 0 (health states worse than death) to 1.0 (full health). Higher scores indicate better health status.

up to 13 months
Quality of life (QoL) data (EQ-5D-5L) Visual Analogue Scale (VAS) Score
時間枠:up to 13 months

Health status will be assessed using the EQ-5D-5L Visual Analogue Scale (VAS). Scores range from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. Higher scores indicate better perceived health

up to 13 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Salah Al-Batran, Prof. Dr.、Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月1日

一次修了 (推定)

2033年1月1日

研究の完了 (推定)

2033年3月1日

試験登録日

最初に提出

2026年10月30日

QC基準を満たした最初の提出物

2026年11月13日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月13日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • IKF-IMMUPARP
  • 2026-528149-36-00 (Ctis)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

No IPD will be shared.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する